

Gene and cell therapy platform, 8/17

August 2017—Horizon Discovery announced progress of its gene and cell therapy platform for contract service and therapeutic applications. The offering will make use of Horizon's suite of gene editing technologies, including CRISPR and its proprietary rAAV and Transposon technologies, to edit pluripotent stem cells and primary human lymphocytes.

Horizon is working with three clients to support preclinical development across a variety of gene and cell therapy treatments in areas of high unmet medical need. This work is expected to contribute more than \$2 million in revenue in 2017, according to a company statement.

[Horizon Discovery](#), 844-655-7800